Insulin is a hormone that causes glucose uptake from the blood through the cells of the liver, muscle and fat tissue to be stored as glycogen in the liver and muscle. Type 1 diabetics’ immune systems destroy pancreatic beta cells: the only cells that can make insulin. The body therefore fails to produce insulin and cannot naturally convert food into energy. Type 2 diabetics have a resistance to insulin, and cells are not able to use the insulin present in the body. The need for insulin increases to the point that the pancreas can no longer produce it. Insulin is therefore a mode of treating both type 1 and type 2 diabetes.
The U.S. insulin market can be segmented by insulin type, yielding four segments: long-acting insulin, rapid-acting insulin, premixed insulin and human insulin. In 2016, the largest segment in the total insulin market was long-acting insulin. Patent expirations and the introduction of new products will lead to higher unit sales growth in this segment, relative to the rapid-acting insulin, premixed insulin and human insulin segments. Combined with steady appreciation of ASP, it is projected that long-acting insulin will be the fastest growing segment in the total insulin market over the forecast period. In terms of volume market share, premixed insulin represents the smallest portion of the total insulin market as well. It is expected that this trend will continue and ASP appreciation will follow the general upward trend of the total insulin market over the forecast period.
'
TABLE OF CONTENTS I
LIST OF FIGURES IV
LIST OF CHARTS VI
EXECUTIVE SUMMARY 1
U.S. DIABETES MONITORING, TREATMENT AND DRUG DELIVERY MARKET OVERVIEW 1
COMPETITIVE ANALYSIS 4
MARKET TRENDS 7
MARKET DEVELOPMENTS 9
PROCEDURE NUMBERS 10
PROCEDURE CODES INVESTIGATED 10
MARKETS INCLUDED 11
KEY REPORT UPDATES 13
VERSION HISTORY 13
RESEARCH METHODOLOGY 14
1.1 RESEARCH SCOPE 14
1.2 IDATA’S 9-STEP METHODOLOGY 14
Step 1: Project Initiation & Team Selection 14
Step 2: Prepare Data Systems and Perform Secondary Research 16
Step 3: Preparation for Interviews & Questionnaire Design 17
Step 4: Performing Primary Research 18
Step 5: Research Analysis: Establishing Baseline Estimates 20
Step 6: Market Forecast and Analysis 21
Step 7: Identify Strategic Opportunities 23
Step 8: Final Review and Market Release 24
Step 9: Customer Feedback and Market Monitoring 25
DISEASE OVERVIEW 26
2.1 INTRODUCTION 26
2.1.1 Types of Diabetes 26
2.1.2 Diabetes Complications 28
2.1.3 Risk Factors Associated with Type 1 and Type 2 Diabetes 30
2.1.4 Signs and Symptoms 31
2.1.5 Diabetes Monitoring 33
2.1.6 Treatment 35
2.1.7 Drug Delivery Systems 36
INSULIN MARKET 38
3.1 INTRODUCTION 38
3.1.1 Insulin Types 38
3.1.1.1 Rapid-Acting Insulin Analogs 38
3.1.1.2 Regular Human Insulin 39
3.1.1.3 Intermediate-Acting Human Insulin 39
3.1.1.4 Long-Acting Insulin Analogs 39
3.1.1.5 Ultra-Long-Acting Insulin Analogs 39
3.1.1.6 Premixed Insulin 39
3.2 MARKET OVERVIEW 41
3.3 MARKET ANALYSIS AND FORECAST 45
3.3.1 Total Insulin Market 45
3.3.1.1 Long-Acting Insulin Market 48
3.3.1.2 Rapid-Acting Insulin Market 51
3.3.1.3 Premixed Insulin Market 54
3.3.1.4 Human Insulin Market 56
3.4 DRIVERS AND LIMITERS 58
3.4.1 Market Drivers 58
3.4.2 Market Limiters 59
3.5 COMPETITIVE MARKET SHARE ANALYSIS 61
ABBREVIATIONS 64
Chart 1 1: Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S., 2013 – 2023 3
Chart 1 2: Diabetes Monitoring, Treatment and Drug Delivery Market Overview, U.S., 2013 &2023 3
Chart 3 1: Insulin Market by Segment, U.S., 2013 – 2023 43
Chart 3 2: Insulin Market Breakdown, U.S., 2016 44
Chart 3 3: Insulin Market Breakdown, U.S.,2023 44
Chart 3 4: Total Insulin Market, U.S., 2013 – 2023 47
Chart 3 5: Long-Acting Insulin Market, U.S., 2013 – 2023 50
Chart 3 6: Rapid-Acting Insulin Market, U.S., 2013 – 2023 53
Chart 3 7: Premixed Insulin Market, U.S., 2013 – 2023 55
Chart 3 8: Human Insulin Market, U.S., 2013 – 2023 57
Chart 3 9: Leading Competitors, Insulin Market, U.S., 2016 63
Figure 1 1: Diabetes Monitoring, Treatment and Drug Delivery Market Share Ranking by Segment, U.S., 2016 (1 of 2) 4
Figure 1 2: Diabetes Monitoring, Treatment and Drug Delivery Market Share Ranking by Segment, U.S., 2016 (2 of 2) 5
Figure 1 3: Companies Researched in this Report, U.S., 2016 6
Figure 1 4: Factors Impacting the Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S. (1 of 2) 7
Figure 1 5: Factors Impacting the Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S. (2 of 2) 8
Figure 1 6: Recent Events in the Diabetes Monitoring, Treatment and Drug Delivery Market, U.S., 2013 – 2016 9
Figure 1 7: Diabetes Monitoring, Treatment and Drug Delivery Markets Covered, U.S., 2016 10
Figure 1 8: Procedure Codes Investigated, U.S., 2016 10
Figure 1 9: Diabetes Monitoring, Treatment and Drug Delivery Markets Covered, U.S., 2016 (1 of 2) 11
Figure 1 10: Diabetes Monitoring, Treatment and Drug Delivery Markets Covered, U.S., 2016 (2 of 2) 12
Figure 1 11: Key Report Updates 13
Figure 1 12: Version History 13
Figure 2 1: Major Types of Diabetes and Related Pathologies, U.S., 2016 27
Figure 2 2: Risk Factors Associated with Type 1 and Type 2 Diabetes, U.S., 2016 31
Figure 2 3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes, U.S., 2016 32
Figure 7 1: Onset, Peak and Duration of Insulin Types, U.S., 2016 40
Figure 3 2: Insulin Market by Segment, U.S., 2013 – 2023 (US$M) 42
Figure 3 3: Total Insulin Market, U.S., 2013 – 2023 46
Figure 3 4: Long-Acting Insulin Market, U.S., 2013 – 2023 49
Figure 3 5: Rapid-Acting Insulin Market, U.S., 2013 – 2023 52
Figure 3 6: Premixed Insulin Market, U.S., 2013 – 2023 54
Figure 3 7: Human Insulin Market, U.S., 2013 – 2023 56
Figure 3 8: Drivers and Limiters, Insulin Market, U.S., 2016 60
Figure 3 9: Leading Competitors, Insulin Market, U.S., 2016 62
Sanofi
Novo Nordisk
Eli Lilly
Medtronic
Johnson & Johnson
Becton Dickinson
Abbott
Roche
DexCom
Ascensia
Insulet
Trividia Health
Tandem
Nova Biomedical
Valeritas
